CER Daily Newsfeed

Under Pressure: Designing Patient Centric Trials That Beat Complexity, Earn Trust, and Improve Retention

(1/5, Sue Harris, IQVIA Blog) comments “...In this climate, patient-centricity is no longer a buzzword—it’s a strategic imperative. Sponsors and sites must move beyond traditional models and confront the realities patients face: logistical burdens, lack of transparency, and limited support throughout the trial journey. When trials are designed with empathy and flexibility, patients are empowered to participate fully, leading to faster recruitment, improved retention, and richer data. More importantly, it means clinical research can deliver outcomes that matter—not just to regulators and sponsors, but to the people whose lives depend on innovation.” Full

Originator & Biosimilar Natalizumab Win English Funding For Highly Active MS

(1/5, Neena Brizmohun, Pink Sheet) reports “...The health technology assessment institute said its recommendation for the multiple sclerosis drugs, Tysabri and Tyruko, highlighted its continued efforts to drive the adoption of biosimilars across the National Health Service.” Subscription Required

RWE4Decisions Symposium 2025: Setting the Scene for Real-World Evidence in EU HTA

(1/5, Joanne Walker, The Evidence Base) reports “At the RWE4Decisions 2025 Symposium ‘Mobilising Real-World Data to Enhance HTA/Payer Decision-Making,’ held online November 20, 2025, stakeholders from across health technology assessment (HTA), payer, regulatory, industry, and patient communities discussed how real-world evidence (RWE) is being applied to support decision-making in Europe. The meeting explored practical experiences and emerging approaches under the EU HTA Regulation (EU HTAR) and the European Health Data Space (EHDS), with discussions spanning governance, methodology, cross-border data use, and patient-relevant evidence.” Full